South Korea · Delayed Price · Currency is KRW SK Biopharmaceuticals Company Description
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders.
The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication.
It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder.
The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
| Country | South Korea |
| Founded | 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 246 |
| CEO | Dong Hoon Lee |
Contact Details
Address: 221, Pangyoyeok-ro Seongnam-si, 13494 South Korea | |
| Phone | 82 31 8093 0114 |
| Website | skbp.com |
Stock Details
| Ticker Symbol | 326030 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7326030004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dong Hoon Lee | Chief Executive Officer, President and Executive Director |
| Jiyoung Jung | Chief Financial Officer and Executive Director |